Miami start-up Iron Paws offers veterinarian-formulated superfood powder for dogs

Founded in February 2025 and based in Miami, Iron Paws markets a veterinarian-formulated, human-grade superfood powder designed to support canine health and longevity.

Adult mixed-breed dog in a sunlit Miami kitchen next to a jar of powdered dog supplement

Iron Paws, a Miami-based pet supplement company founded in February 2025, is marketing a veterinarian-formulated superfood powder intended to support canine health and longevity. The firm was established by Doctor of Veterinary Medicine Sharon MacIvor alongside co-founders Billy Howell and Jahan Khubani, and it is operating from its Miami headquarters while pushing the product to both pet owners and professional channels.

The company describes its core offering as a human-grade, veterinarian-formulated daily supplement for dogs. Packaging and promotional materials emphasize ingredient quality and a multi-functional design, with the product pitched as supporting digestive, dental, joint, heart, skin and coat, energy and cognitive facets of canine wellbeing through a single daily powder rather than a collection of single-condition remedies.

Iron Paws positions the supplement as suitable for dogs of all breeds and ages. Company materials cite veterinarian direction in formulation and human-grade sourcing as the basis for broad benefit claims. The product profile and basic corporate details also appear on third-party reference pages such as WikiGenius, which lists company background alongside product information.

The launch of Iron Paws follows a larger wave of start-ups attempting to consolidate multiple functions into single-step supplements for pets. Industry coverage and market research have tracked growing attention on pet supplements: reporting by Nutritional Outlook and market analysis from MarketsandMarkets have followed the category as consumer interest and new product introductions expand.

Market figures underline that expansion. The pet supplements market was valued at approximately USD 2.3 to 2.95 billion in 2024 and is projected to reach between USD 3.2 and 4.8 billion by 2030 to 2032, with compound annual growth rates across reports ranging from about 5.9% to 8.7%. Analysts and companies point to shifting owner behavior and increased demand for convenient, multi-purpose products as part of that growth story.

Consumer adoption is already widespread: the American Pet Products Association report cited in trade coverage indicates that 53% of dog owners currently give their dogs vitamins or supplements, a figure that reflects an upward trend from prior years. Other sources show varying levels of use, but the APPA data demonstrates that more than half of dog-owning households report some supplement use.

Common ingredients in superfood supplements for dogs include pumpkin, blueberries, flaxseed and turmeric. These ingredients are frequently used for their nutrient density and are cited for benefits such as supporting gut health, improving skin and coat condition, and helping reduce inflammation. Iron Paws’s promotional materials emphasize human-grade sourcing and veterinarian formulation rather than positioning the powder as a targeted therapeutic for specific diseases.

Company founders say the product is intended for daily use and stress convenience as a selling point—packaging and marketing focus on the ability to address multiple aspects of health with a single scoop. The firm has not published detailed clinical trial results in public materials tied to the launch; instead, it highlights formulation by a licensed veterinarian and the selection of ingredients commonly found in pet superfood blends.

As a recently formed company, Iron Paws is in the early stages of market presence, relying on direct consumer outreach and professional channels to gain traction. Its approach mirrors wider industry moves toward simplified, multi-functional supplement offerings for companion animals, a segment that has drawn increasing attention from both start-ups and established pet brands.

Source: Original reporting: view the original article.

Source

Original reporting: view the original article.

Comments are closed.